Levosimendan Accord

Levosimendan, the active ingredient in Levosimendan Accord, is a calcium sensitizer presented as an intravenous solution for intravenous use. It enhances cardiac contractility and induces vasodilation, and is employed in the management of acute decompensated heart failure in adult patients who require rapid hemodynamic support.

GNH USA supplies Levosimendan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality assurance through rigorous testing and adherence to global regulatory standards.

Levosimendan, a calcium sensitizer, is employed in the management of heart failure syndromes that benefit from increased myocardial contractility and vasodilation. Acute decompensated heart failure: improves cardiac output and reduces symptoms of low perfusion. Severe chronic heart failure with low output: provides symptomatic improvement when standard inotropes are inadequate. Cardiogenic shock: serves as short‑term inotropic support while awaiting definitive therapy. Post‑cardiac surgery low‑output syndrome: helps restore adequate circulation in the immediate postoperative period.

Levosimendan may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Hypotension - Headache - Nausea - Tachycardia

Serious or Rare Side Effects: - Severe hypotension - Ventricular arrhythmias - Myocardial ischemia - Allergic reactions

Use of levosimendan requires careful clinical monitoring. - Monitor blood pressure: watch for hypotension, especially during initial infusion. - Assess cardiac rhythm: risk of tachyarrhythmias warrants ECG surveillance. - Avoid in severe hypotension: contraindicated when systolic pressure is markedly low. - Use caution in renal impairment: dose adjustment may be necessary. - Use caution in hepatic impairment: consider reduced clearance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid): - Concomitant vasodilators: may cause profound hypotension. - Calcium channel blockers: increased risk of arrhythmias. - Strong inotropic agents: additive cardiac stimulation.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors: monitor blood pressure closely. - Nitrates: observe for excessive vasodilation.